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The molecular biology of renin, prorenin, and the renin gene have been studied. A tissue-
specific pattern of expression was found in rat and human tissues. In the human placenta, the
transfected and endogenous renin promoters are active, and renin mRNA levels and transfected
promoter activity are increased by a calcium ionophore plus cAMP. Cultured pituitary AtT-20
cells transfected with a preprorenin expression vector mimick renal renin release by converting
prorenin to renin and releasing renin in response to 8Br-cAMP. Studies with mutant renin genes
suggest that the body of renin directs renin to the regulated secretory pathway, and renin
glycosylation affects its trafficking. Chinese hamster ovary cells were used to produce recombi-
nant prorenin. Infused prorenin was not converted to renin in monkeys. Renin crystals were used
to determine its three-dimensional structure. Renin resembles other aspartyl proteases in the
active site and core, but it differs in other regions that probably explain renin's unique substrate
specificity. Based on structural and mutational analysis, a model for human prorenin was built
that suggests lysine -2 of the prosegment interacts with active site aspartate residues, and that
the prosegment inactivation ofrenin is stabilized by binding ofan amino terminal ,B strand into a
groove on renin.
INTRODUCTION
The renin angiotensin system is involved extensively in regulating blood pressure,
fluid balance, and other cardiovascular and renal functions [1,2]. It is critical for the
body's responses to fluid loss and shock, and abnormalities in it are implicated in the
pathological derangements ofhypertension, heart failure, and other disorders. Renin is
rate-limiting for the production of angiotensin II, the major active component of the
system [1,2]. In the circulation and possibly at other local sites, renin cleaves
angiotensinogen to release the decapeptide angiotensin I [1,2] that is converted to
angiotensin II by converting enzyme. Since converting enzyme inhibitors are widely
used in treating hypertension and heart failure [3], renin is also a target for blockade
by pharmaceuticals [4,5]. The effects ofrenin and converting enzyme inhibitors could
even differ, since converting enzyme acts on substrates, such as bradykinin [1,3], in
addition to angiotensin I, whereas renin acts only on one known substrate in spite of its
homology with other aspartyl proteases, such as pepsin that have other substrates
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[4-111. Knowledge of the structure of renin could facilitate the design of such
inhibitors.
The major source of circulating renin in man is the renal juxtaglomerular cells, in
which renin mRNA is translated into preprorenin that is processed to prorenin upon its
insertion into the rough endoplasmic reticulum [1,2,12-15]; prorenin is catalytically
inactive [12,16]. Some prorenin is released [17,18], but much of it is converted in the
juxtaglomerular cells to active renin by proteolytic removal of the 43 amino acid
prosegment [10,11,16-18]. This renin can be stored and released in response to such
provocative stimuli as beta-adrenergic activation [18,19]. Elements of the renin
angiotensin system are also expressed in extrarenal tissues, and there is growing
suspicion that local renin angiotensin systems play important roles [12,20-26]. At
external sites, prorenin rather than renin is predominately released. Thus, knowledge
of how the expression of the renin gene is controlled, renin release is regulated, and
conversion of prorenin to renin occurs is relevant to understanding the role of renin in
physiological and pathological states. To address these issues, we have been examining
aspects of renin and its gene.
CLONING AND STRUCTURAL ANALYSIS OF THE HUMAN RENIN
GENE
To obtain human renin gene sequences, we earlier cloned the human renin
chromosomal gene [10], using a mouse cDNA probe [27], and later cloned a human
renin cDNA [28]. The chromosomal gene was sequenced in the 5'- and 3'-flanking
DNA, the exons, and portions of the introns. The gene spans over 11 kb of DNA,
contains ten exons separated by nine introns, and there is repetitive DNA in the 5'- and
3'-flanking regions (Fig. 1). The gene shows organization similar to that encoding the
related pepsinogen [8].
TRANSCRIPTIONAL CONTROL OF RENIN GENE EXPRESSION
Transcriptional control of renin gene expression involves factors that direct its
tissue-specific pattern of expression and that regulate the level of expression in
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response to regulatory signals. The tissue-specific expression ofthe gene in the rat was
examined by hybridization histochemistry and immunocytochemistry [29]. The gene
is most actively expressed in the renaljuxtaglomerular cells, but there are lower levels
ofexpression in theadrenal glomerulosa, testicular leydig cells, ovary, and anterior and
intermediate pituitary. In the human, expression was detected in placental cells
[30,31]. (The specific cell type has not yet been rigorously established.) These results
suggest a highly tissue-specific pattern of expression. A transfected gene containing
the renin promoter and chloramphenicol acetyltransferase (CAT) coding sequences
(renin-CAT) was expressed by the placental cells, although it is not clear that this
promoter is sufficient for directing tissue-specific expression ([31]; Fig. 1).
Since renal renin release is regulated by such agents as 3-adrenergic agonists and
angiotensin II that act through second messengers such as cAMP and calcium ion [1],
we examined whether some of these second messengers could affect either renin
mRNA levels or promoter activity. In the placental cells, a calcium ionophore
increased endogenous renin mRNA levels, and the increase was greater with the
ionophore plus forskolin that activates adenylate cyclase [311. The combination of
forskolin plus a phorbol ester that activates C-kinase also increased renin mRNA
levels. Thus, these messengers could affect renin production in part by regulating renin
mRNA levels. These influences could be due to effects on the renin promoter, since
expression of the renin-CAT construct, when transfected with calcium phosphate
precipitation (which increases calcium ion uptake), was increased by forskolin (Fig. 1).
The effect was observed with constructs containing as few as 100 bp of the proximal
renin 5'-flanking DNA.
POST-TRANSCRIPTIONAL EVENTS IN RENIN GENE EXPRESSION
Since cultured human juxtaglomerular cells that produce prorenin and process it to
renin are not available, we have developed a model system to study regulated release of
renin by transfecting cultured cells with a genethat expresses human renin genecoding
sequences [32]. Thus genes containing the human metallothionein or Rous sarcoma
virus promoters that drive expression of preprorenin coding sequences have been
transfected intocultured pituitary AtT-20 or Chinese hamster ovary (CHO) cells [32].
AtT-20 cells process other preproteins such as proopiomelanocortin or proinsulin, and
release of the mature hormone is controlled in these cells by secretagogues [33]. In
contrast, CHO cells do not process prohormones such as these, and the secretion ofthe
proteins is not affected by secretagogues [33].
It was ofparticular interest to determine whether prorenin was converted to renin in
these cells, because the only known sources ofplasma renin in humans and rats are the
kidneys [l,12,14,15]. Most other tissues that have been found to express the renin gene
apparently release only prorenin [12,14,20-26,29-31]. Thesedata could imply that the
prorenin processing enzyme has a highly restricted tissue distribution; however, the
prorenin synthesized by the transfected AtT-20 cells was cleaved to active renin at the
natural cleavage site (documented by amino terminal sequencing), and the release of
renin was regulated by the same stimulus (cAMP; in this case, 8Br-cAMP) that
promotes the release of renal renin [32]. Similar results were obtained by Pratt et al.
[34]. Thus, prorenin processing enzymes are not restricted to the kidney, and certain
aspects of regulated renin release can be reconstituted in the AtT-20 cells, which can
therefore serve as a useful model.
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ROLE OF GLYCOSYLATION IN PRORENIN AND RENIN RELEASE
Renin is known to be glycosylated [28,36,37]. In the rat, several different forms of
glycosylated renin have been identified, and these have been proposed to vary in their
clearance from the circulation [37]. The presence of sugar moieties on other proteins
has also been shown to affect their intracellular trafficking [36]. This presence can
promote the binding of the proteins to the mannose-6-phosphate receptor on the
lysosome, with consequent uptake into the lysosome and degradation [36]. In our
studies with recombinant DNA-produced prorenin, treatment of prorenin with endo-
glycosidase F that removes much of the carbohydrate did not activate prorenin,
suggesting that the sugar moieties were not involved in activating prorenin [28,35].
Faust et al. presented evidence, using human prorenin expressed in Xenopus oocytes,
that a significant amount ofthe prorenin produced is targeted to the lysosome where it
is degraded [36].
To explore more rigorously the roleofglycosylation in prorenin and renin trafficking
in the cell and activation, we prepared a mutated prorenin coding vector in which one
or both of the only two glycosylation sites of renin (asparagine residues at positions 5
and 75) were changed to serine residues [38]. The mutant deglycosylated prorenins
were then expressed in CHO and AtT-20 cells. No differences between native and
mutant deglycosylated prorenin secretion or activity were observed with CHO cells. In
contrast, a higher proportion of the total prorenin and renin produced in the AtT-20
cells was active renin. Thus, the sugar moieties do not appear to contribute to the
inactivation or activation of prorenin, but they may affect the intracellular trafficking
of prorenin and possibly the intracellular processing of prorenin. If the sugar moieties
do target prorenin to the lysosome, then the AtT-20 cell data could imply that the
absence of the sugar moieties could target more of the prorenin to the regulated
secretory granules, with consequent processing to renin and release in response to
secretagogue stimulation.
ROLE OF THE SIGNAL PEPTIDE AND PROSEGMENT SEQUENCES IN
RENIN TRAFFICKING
To determine the role of the signal peptide and prosegment sequences in the
intracellular trafficking of renin (Fig. 2), we prepared two mutant renin genes [38].
One ofthesecontained a deleted prosegment and theothercontained the signal peptide
sequences of the mouse IgM immunoglobulin, which is not targeted to the regulated
secretory pathway. These genes were transfected into AtT-20 cells. The prosegment-
deleted gene expressed active renin whose release was increased by secretagogue
stimulation. The gene containing the immunoglobulin leader sequence expressed both
prorenin and renin, and renin release was increased by secretagogue treatment. These
results suggest that the signals directing renin to the regulated secretory pathway are
not contained within the signal peptide or prosegment sequences and therefore must be
contained within the body of renin.
RECOMBINANT PRODUCTION OF PRORENIN AND RENIN
Renin and prorenin circulate at very low levels, and only small quantities of these
proteins are available from natural sources for purification. To obtain prorenin and
renin for purification, we developed CHO cell lines that express larger quantities of
human preprorenin [28]. The cells were co-transfected with two vectors. One of these
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contained the metallothionein promoter that is highly active in these cells, human
preprorenin coding sequences, and a 3'-terminal region from the human growth
hormone gene. The other vector contained the entire metallothionein gene. Metallo-
thionein protects cells from being killed by cadmium ions. Thus, by growing cells in
progressively increasing cadmium ion concentrations, cell lines can be selected in
which the metallothionein gene is amplified. Because the preprorenin and metallo-
thionein vectors are usually integrated into the DNA together, both genes will be
amplified by the cadmium ion selection, and thus cadmium-resistant cells will produce
higher levels of prorenin. In this way, lines that express relatively larger quantities of
prorenin were obtained from the original transfected cells. Prorenin was subsequently
isolated from these cells and was either purified as such or converted to renin by trypsin
treatment and purified [7,29,35]. The properties of the purified prorenin and renin
were identical to those of naturally occurring renin in all of a number of parameters
studied, such as mobility on several gels, apparent carbohydrate content, inhibition by
pepstatin that blocks renin activity, substrate affinity, and activation by trypsin
[16,28,35].
ACTIVITY OF INFUSED PRORENIN
There is controversy as to whether prorenin can be converted to renin in the
circulation. Whereas most investigators have concluded that there is no conversion of
prorenin to renin in the circulation [1,12,14,15], it has been reported that the rat
kidney releases a protease that cleaves renin in the circulation [39]. Others have
proposed that prorenin might have in vivo activity, for example, through reversible
activation or after its uptake by peripheral tissues [12,21,40]. To address issues such as
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these, prorenin was infused into rhesus monkeys over a 40-minute period [41]. The
infusion resulted in three- to fourfold elevationsofprorenin levels. There was, however,
no increase in plasma renin levels and no response to several potential sequelae ofrenin
actions to generate angiotensin II production, such as changes in blood pressure,
aldosterone release, or urinary sodium or potassium secretion. These studies therefore
suggest that circulating prorenin is not converted to renin and is generally inactive in
terms ofclassical renin activity.
X-RAY CRYSTALLOGRAPHIC STRUCTURE OF HUMAN RENIN
The availability of prorenin and renin produced by recombinant DNA methods
provided a stimulus to determine the three-dimensional structure of human renin. To
do this, the recombinant DNA-produced and purified renin from the CHO cells was
first crystallized [7]. By obtaining highly purified renin and following about 1,500
crystallization trials, crystals acceptable for X-ray diffraction experiments were
obtained [7]. Solution ofthe structure was facilitated by the availability ofcoordinates
ofthe closely related porcine pepsinogen [6]. Based on these coordinates and the amino
acid sequence homology between renin and pepsinogen, a model for human renin was
constructed. The placement ofthis model in the renin crystallographic cell was carried
out by the molecular replacement technique. The electron density maps obtained from
the X-ray diffraction data and molecular replacement phases revealed that the model
was correct for those regions of renin expected to be most similar to pepsin, for
example, in the active site and the hydrophobic core of the molecule. The agreement
was much worse for regions where the sequence homology is weak, however; i.e., those
regions where renin is unique. These regions are probably of the greatest interest in
explaining the unique substrate specificity of renin and for designing inhibitors of
renin. These results also point to limitations of current computer modeling and other
methods to define tertiary structures. To improve the structure of renin, molecular
dynamics refinement techniques that included the crystallographic data as a restraint
were used to resolve the differences between the model and the data. The final stages
of refinement were carried out at 2.5-angstrom resolution by using conventional
restrained parameters least-squares algorithms. The current model (Fig. 3) still
contains poorly defined surface loops, whereas the interior of the molecule is well
defined.
MODEL FOR PRORENIN AND MECHANISMS OF PROSEGMENT
ACTIVATION
Prorenin has very weak renin catalytic activity [12,16,35]. This low level ofactivity
is due to inhibition of the active site of the enzyme by the prosegment [6,12,42].
Pepsinogen is analogous to renin in this respect, and for this zymogen the prosegment
folds into a cleft in the protein that harbors the two aspartate residues ofthe active site.
The amino terminal segment forms part ofa ,B-pleated sheet located in the back ofthe
molecule; it then forms two a helices that fit into a hydrophobic pocket near the
aspartate residues of the active site [6]. When the prosegment of pepsinogen is
removed, the amino terminus of the mature pepsin molecule undergoes an enormous
conformational change in which the amino terminal amino acids move into the same
d-sheet structure previously occupied by the prosegment [6]. Inspection of the
structure of renin [7] suggests that its amino terminal amino acids occupy an
analogous position relative to the renin molecule. Thus, it is likely that a similar
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FIG. 3. Structure of human renin. Data from Sielecki et al. [7]. Shown is the alpha-carbon tracing ofthe
molecule. The overall croissant-like shape ofthe molecule with a cleft is apparent. In the interior ofthe cleft
are the active site aspartate residues (D32 and D215) whose side chains are also portrayed. The amino
terminus (NTER) that is folded around the back ofthe molecule fits into a pocket proposed to beoccupied by
the amino terminus of prorenin. The carboxyl terminus (CTER) and the single monosaccharide (GLCN)
bonded to Asn 67 (N67) that remained on the glycosidase-treated renin used for the structure analysis are
also indicated. The numbering system used here is based on that ofporcine pepsin. Thus, Asn 67 is Asn 75 of
renin, Asp 32 is Asp 38 ofrenin, and Asp 215 is Asp 226 in renin.
situation exists with prorenin. Based on a comparison of the structures of renin and
pepsinogen, it appears the lysine at -2 of the prorenin prosegment is the amino acid
that forms ionic interactions with the active site aspartate residues and that a : strand
of more amino terminal amino acids ofthe prosegment ofprorenin fits into the ,B sheet
on the back surface of the molecule in a manner analogous to that found in
pepsinogen.
To assess the importance ofthese interactions, we prepared two mutant renin genes.
In one of these, the lysine at -2 was converted to an alanine. This gene, when
transfected into CHO cells, expressed only prorenin, suggesting that the putative
interaction ofthe lysine at the active site is not critical for prosegment inactivation. In
contrast, when an arginine at prosegment residue -32 in the proposed ,B sheet was
changed to an aspartic acid residue that would beexpected to create a charge repulsion
effect on the interaction of the ,B sheet with the body of the molecule, the CHO cells
released active prorenin. These results suggest that the /-sheet interactions with the
body of the molecule are important for keeping the prosegment amino acids fitted into
the active site, where they presumably block the catalytic activity of the enzyme by
preventing the substrate (angiotensinogen) from reaching the active site.
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